Der Hautarzt

, Volume 61, Issue 8, pp 705–718 | Cite as

Antikoagulation in der Dermatologie

CME Weiterbildung · Zertifizierte Fortbildung

Zusammenfassung

Das Gerinnungssystem schützt den Körper über komplex regulierte Prozesse vor unkontrollierten Blutverlusten. Im Falle einer Verletzung schaltet das Gerinnungssystem in Bruchteilen von Sekunden von kontrolliertem Blutfluss auf akute Gerinnung und Thrombusbildung mit dem Ziel der Blutflussstillung um. Nur geringe Verschiebungen der ausgewogenen Balance zwischen Gerinnung und freiem Blutfluss machen den Unterschied zwischen unkontrolliertem Blutverlust und ggf. fatalen thrombembolischen Ereignissen aus. Eine iatrogene Beeinflussung dieses Systems ist durch eine Vielzahl an Therapeutika möglich. Der vorliegende Beitrag möchte dem klinisch tätigen Dermatologen die Grundzüge der Gerinnung auffrischend darstellen und eine Hilfestellung nicht nur auf dem Gebiet der Thromboseprophylaxe geben, sondern auch weitere Anwendungsbereiche von therapeutisch genutzten Antikoagulanzien aufzeigen.

Schlüsselwörter

Hämostase Antikoagulation Thromboseprophylaxe Gerinnungssystem Thrombembolische Ereignisse 

Dermatologic asepcts of anticoagulation

Abstract

The coagulation system protects the body from uncontrolled blood loss by means of highly regulated processes. In case of an injury the coagulation system instantly switches from controlled blood flow to acute coagulation and thrombus formation with the goal of stopping the blood loss. Minor changes in this well-maintained equilibrium of coagulation and blood flow tip the balance towards uncontrolled blood loss or even fatal thromboembolic events. Iatrogenic manipulation of this highly regulated system is possible with a variety of therapeutic agents. We review the basics of coagulation physiology and then discuss dermatologically relevant aspects of thrombosis prevention, as well as the use of anticoagulants to treat dermatologic diseases.

Keywords

Haemostasis Anticoagulation Thrombosis prophylaxis Coagulation system Thromboembolic events 

Notes

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Bergmeier W, Piffath CL, Goerge T et al (2006) The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc Natl Acad Sci U S A 103(45):16900–16905CrossRefPubMedGoogle Scholar
  2. 2.
    Chauhan AK, Goerge T, Schneider SW, Wagner DD (2007) Formation of platelet strings and microthrombi in the presence of ADAMTS-13 inhibitor does not require P-selectin or beta3 integrin. J Thromb Haemost 5(3):583–589CrossRefPubMedGoogle Scholar
  3. 3.
    Schneider SW, Nuschele S, Wixforth A et al (2007) Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci U S A 104(19):7899–7903CrossRefPubMedGoogle Scholar
  4. 4.
    Arnout J, Hoylaerts MF, Lijnen HR (2006) Haemostasis. Handb Exp Pharmacol 176 Pt 2:1–41CrossRefGoogle Scholar
  5. 5.
    Butenas S, ‚t Veer C van, Mann KG (1997) Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases. J Biol Chem 22;272(34):21527–21533Google Scholar
  6. 6.
    Kasthuri RS, Taubman MB, Mackman N (2009) Role of tissue factor in cancer. J Clin Oncol 27(29):4834–4838CrossRefPubMedGoogle Scholar
  7. 7.
    Tang H, Ivanciu L, Popescu N et al (2007) Sepsis-induced coagulation in the baboon lung is associated with decreased tissue factor pathway inhibitor. Am J Pathol 171(3):1066–1077CrossRefPubMedGoogle Scholar
  8. 8.
    Deutsche Gesellschaft für Chirurgie et al (o J) AWMF Leitlinie „Prophylaxe der venösen Thromboembolie“ (VTE) [Internet]Google Scholar
  9. 9.
    Zaghdoudi I, Rezgui M, Zouaoui W et al (2008) Incidence of deep venous thrombosis in patients with erysipelas of the leg: Prospective study of 30 cases in an emergency department. Pathophysiol Haemost Thromb 36(5):271–274CrossRefPubMedGoogle Scholar
  10. 10.
    Perrot JL, Perrot S, Laporte Simitsidis S (2001) Is anticoagulant therapy useful when treating erysipelas? Ann Dermatol Venereol 128(3 Pt 2):352–357PubMedGoogle Scholar
  11. 11.
    Falanga A, Zacharski L (2005) Deep vein thrombosis in cancer: The scale of the problem and approaches to management. Ann Oncol 16(5):696–701CrossRefPubMedGoogle Scholar
  12. 12.
    Grazziotin MU, Turnipseed WD (2002) Arterial tumor embolism caused by metastatic melanoma: case report and literature review. J Vasc Surg 36(1):191–193CrossRefPubMedGoogle Scholar
  13. 13.
    Machnick S, Butz T, Bracht M van et al (2009) Multiple cardiac metastases from a malignant melanoma causing consecutive pulmonary embolism. Herz 34(5):410–411PubMedGoogle Scholar
  14. 14.
    Valente M, Pozzi-Mucelli F, Ponte E (2001) Venous thromboembolism and melanoma. Minerva Cardioangiol 49(5):327–333PubMedGoogle Scholar
  15. 15.
    Arbeit JM, Lowry SF, Line BR et al (1981) Deep venous thromboembolism in patients undergoing inguinal lymph node dissection for melanoma. Ann Surg 194(5):648–655CrossRefPubMedGoogle Scholar
  16. 16.
    Görge T, Schneider SW (2008) Tumor-induzierte Thrombophilie. Zellbiologische Grundlagen und klinischer Ausblick. Phlebologie 36(3):142–147Google Scholar
  17. 17.
    Barret JP, Dziewulski PG (2006) Complications of the hypercoagulable status in burn injury. Burns 32(8):1005–1008CrossRefPubMedGoogle Scholar
  18. 18.
    Jung M, Kippes W, Messer G et al (1999) Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence. J Am Acad Dermatol 41(2 Pt 1):266–268CrossRefPubMedGoogle Scholar
  19. 19.
    Hussain SK, Sundquist J, Hemminki K (2010) Incidence trends of squamous cell and rare skin cancers in the swedish national cancer registry point to calendar year and age-dependent increases. J Invest Dermatol (in press)Google Scholar
  20. 20.
    Gohel MS, Taylor M, Earnshaw JJ et al (2005) Risk factors for delayed healing and recurrence of chronic venous leg ulcers – an analysis of 1324 legs. Eur J Vasc Endovasc Surg 29(1):74–77CrossRefPubMedGoogle Scholar
  21. 21.
    Sommer F, Hensen P, Bockenholt B et al (2007) Underlying diseases and co-factors in patients with severe chronic pruritus: a 3-year retrospective study. Acta Derm Venereol 87(6):510–516CrossRefPubMedGoogle Scholar
  22. 22.
    Stinnett JM, Pendleton R, Skordos L et al (2005) Venous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates. Am J Hematol 78(3):167–172CrossRefPubMedGoogle Scholar
  23. 23.
    Sunderkotter C, Groot K de (2008) Therapy of vasculitides and vasculopathies. Hautarzt 59(5):382–393CrossRefPubMedGoogle Scholar
  24. 24.
    Maguiness S, Guenther L (2002) Kasabach-Merritt syndrome. J Cutan Med Surg 6(4):335–339CrossRefPubMedGoogle Scholar
  25. 25.
    Auletta MJ, Headington JT (1988) Purpura fulminans. A cutaneous manifestation of severe protein C deficiency. Arch Dermatol 124(9):1387–1391CrossRefPubMedGoogle Scholar
  26. 26.
    Fujikawa K, Suzuki H, McMullen B, Chung D (2001) Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 98(6):1662–1666CrossRefPubMedGoogle Scholar
  27. 27.
    Deutsche Gesellschaft für Angiologie und weitere AWMF-Mitgliedsgesellschaften (o J). Diagnostik und Therapie der Bein- und Beckenvenenthrombose und Lungenembolie. [Internet]. 01/2005Google Scholar
  28. 28.
    Mueller RL (2004) First-generation agents: Aspirin, heparin and coumarins. Best Pract Res Clin Haematol 17(1):23–53CrossRefPubMedGoogle Scholar
  29. 29.
    McCarter JC, Bingham JB, Meyer OO (1944) Studies on the hemorrhagic agent 3,3’-methylenebis (4-hydroxycoumarin): IV. the pathologic findings after the administration of dicumarol. Am J Pathol 20(3):651–659PubMedGoogle Scholar
  30. 30.
    Best CH (1959) Preparation of heparin and its use in the first clinical cases. Circulation 19(1):79–86PubMedGoogle Scholar
  31. 31.
    Hirsh J (1991) Heparin. N Engl J Med 324(22):1565–1574CrossRefPubMedGoogle Scholar
  32. 32.
    Fabris F, Luzzatto G, Stefani PM et al (2000) Heparin-induced thrombocytopenia. Haematologica 85(1):72–81PubMedGoogle Scholar
  33. 33.
    Kishimoto TK, Viswanathan K, Ganguly T et al (2008) Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 358(23):2457–2467CrossRefPubMedGoogle Scholar
  34. 34.
    Mammen EF (1999) Low molecular weight heparins and heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 5(Suppl 1):S72–S75CrossRefPubMedGoogle Scholar
  35. 35.
    Levine M, Gent M, Hirsh J et al (1996) A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334(11):677–681CrossRefPubMedGoogle Scholar
  36. 36.
    Schmid P, Fischer AG, Wuillemin WA (2009) Low-molecular-weight heparin in patients with renal insufficiency. Swiss Med Wkly 139(31–32):438–452Google Scholar
  37. 37.
    Schinzel H (2007) Einsatz von niedermolekularen Heparinen bei Niereninsuffizienz. Vascular Care 01/2007:4–17Google Scholar
  38. 38.
    Lim W (2010) Using low molecular weight heparin in special patient populations. J Thromb Thrombolysis 29(2):233–240CrossRefPubMedGoogle Scholar
  39. 39.
    Dager WE, Andersen J, Nutescu E (2004) Special considerations with fondaparinux therapy: heparin-induced thrombocytopenia and wound healing. Pharmacotherapy 24(7 Pt 2):88S–94SCrossRefPubMedGoogle Scholar
  40. 40.
    Perzborn E, Roehrig S, Straub A et al (2010) Rivaroxaban: a new oral factor xa inhibitor. Arterioscler Thromb Vasc Biol 30(3):376–381CrossRefPubMedGoogle Scholar
  41. 41.
    Schumacher WA, Luettgen JM, Quan ML, Seiffert DA (2010) Inhibition of factor XIa as a new approach to anticoagulation. Arterioscler Thromb Vasc Biol 30(3):388–392CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Klinik und Poliklinik für DermatologieUniversitätsklinikum MünsterMünsterDeutschland
  2. 2.Klinik und Poliklinik für Dermatologie, Venereologie und Allergologie, Experimentale Dermatologie, Medizinische Fakultät MannheimRuprecht-Karls-Universität Heidelberg, MannheimMannheimDeutschland

Personalised recommendations